AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug
AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug
Vandana SinghSat, April 25, 2026 at 5:01 PM UTC
0
AbbVie Inc. shares are down during Friday’s premarket session following a Complete Response Letter (CRL) from the FDA regarding the Biologics License Application for trenibotulinumtoxinE (TrenibotE).
The letter requested additional information about manufacturing processes but did not raise any safety or efficacy concerns.
FDA Rejection Hits AbbVie Wrinkle Drug Filing
The FDA’s CRL does not require additional clinical studies, and AbbVie is confident in addressing the agency’s feedback promptly.
The company expects to submit a thorough response in the coming months, while regulatory reviews for TrenibotE in other countries are ongoing.
Don't Miss:
A single bad hire can set a startup back years. Here are the 5 hires founders most often misjudge — and why
Still Learning the Market? These 50 Must-Know Terms Can Help You Catch Up Fast
TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (the earliest assessment time) and a short duration of effect of 2-3 weeks.
In April 2025, the U.S.-based large-cap drug maker submitted the FDA application for TrenibotE for moderate to severe glabellar lines (frown lines).
$1.4 Billion Manufacturing Investment Signals Long-Term Focus
On Wednesday, AbbVie announced a $1.4 billion investment to build a pharmaceutical manufacturing campus in North Carolina.
The campus will integrate advanced manufacturing and laboratory technologies with artificial intelligence (AI) to support the production of AbbVie’s immunology, neuroscience, and oncology medicines.
Advertisement
See Also: Avoid the #1 Investing Mistake: How Your ‘Safe' Holdings Could Be Costing You Big Time
Construction will begin this year, with completion expected by the end of 2028.
The project is part of the company’s $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade.
SVP Manufacturing To Anchor Initial Phase
The first phase of construction will include small-volume parenteral (SVP) drug product manufacturing facilities.
SVPs are sterile injectable pharmaceutical products with volumes typically less than 100 mL, including vials, prefilled cartridges, and prefilled syringes containing medicines for injection or infusion.
image via Shutterstock
Read Next:
Skip the Regrets: The Essential Retirement Tips Experts Wish Everyone Knew Earlier.
Thinking about ETFs? See what investment risks you should be aware of before you buy.
"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!
Get the latest stock analysis from Benzinga:
APPLE (AAPL): Free Stock Analysis Report
TESLA (TSLA): Free Stock Analysis Report
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Source: “AOL Money”
